SURGICAL INNOVATIONS GROUP PLC

• ◆

  4 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. SURGICAL INNOVATIONS GROUP PLC 1998-07-07 → present
2. HAEMOCELL PLC 1988-11-16 → 1998-07-07
3. NEWPOLL PUBLIC LIMITED COMPANY 1988-09-20 → 1988-11-16

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Saffery LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors continue to adopt the going concern basis in the preparation of the financial statements. The Directors have prepared forecasts for the period to April 2027 based on a full evaluation of the Group's trading activities and costs base, sensitised to reflect a rational judgement of the level of inherent risk. The Board is satisfied that there is headroom including testing any sensitivities under reasonably possible scenarios, and the Directors conclude that it continues to be appropriate to prepare the Annual Report and Accounts on a going concern basis.”

Group structure

1. SURGICAL INNOVATIONS GROUP PLC · parent
   1. Surgical Innovations Limited 100% · UK · Design and manufacture of minimally invasive devices
   2. Haemocell Limited 100% · UK · Design and manufacture of Autologous blood products
   3. Elemental Healthcare Ltd 100% · UK · Distribution of innovative Medical products

Significant events

• “Principal decision 1 - Setting of annual financial budget and reforecasting. ...key discussions revolved around the Going Concern principle and the Group's ability to maintain adequate cash resources over the foreseeable 12 months. The importance of existing support from bank borrowings, which underpin this ability, was also emphasised. The Group continue to use an invoice discounting facility of £1m providing additional headroom, in addition to a CBILS loan, due to be fully repaid in 2026.”
• “Principal decision 2 - Medical Device Regulations certification (MDR). The regulatory environment remains dynamic... The Group, however, has already made significant progress and has successfully achieved MDR certification...”
• “Principal decision 3 - Board succession planning. ...During 2025 the Board retained the services of an independent executive search firm to appoint a new CFO with the requisite skills and experience for appointment in 2025.”
• “Principal decision 4 - Operational review. Operational challenges continue to exist. Supply chain is showing prolonged lead times on components affecting production efficiency. However, strengthened relationships with key suppliers, supported by strategic investments in personnel, have led to noticeable improvements.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

0

last 24 months

Officers appointed

5

last 12 months

Officers resigned

4

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.